|
|
Article: Celgene Corporation Reports Record Operating Performance and Key Clinical and Regulatory Progress.
- Article from:
- PR Newswire
- Article date:
- July 28, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Record Second Quarter Revenue and Profits:
- Total Revenue Increased 66 Percent Year-Over-Year
- Net Operating Profits Increased More Than 300 Percent Year-Over-Year
- Earnings Per Diluted Share More Than Doubled Year-Over-Year
- Company Affirms 2005 Financial Targets
REVLIMID(R), THALOMID(R) and FOCALIN XR(TM) Clinical and Regulatory Programs Advanced:
- FDA Granted Priority Review for REVLIMID NDA for Treatment of Low and Intermediate Risk MDS with Deletion 5q Chromosomal Abnormality; PDUFA date October 7, 2005